X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.reuters.com/markets/deals/eli-lilly-sell-low-blood-sugar-drug-amphastar-2023-04-24/
https://www.prnewswire.com/news-releases/zucara-therapeutics-announces-publication-of-preclinical-study-demonstrating-zt-01s-ability-to-restore-glucagon-release-in-type-1-diabetes-301477414.html
https://www.prnewswire.com/news-releases/sciwind-biosciences-completes-enrollment-in-phase-2-clinical-trial-of-xw003-in-type-2-diabetes-patients-301439851.html
https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-preclinical-data-on-novel-dual-glp-1gip-agonists-at-obesityweek-2021-301407205.html
https://endpts.com/eli-lilly-ordered-to-pay-royalties-on-blockbuster-diabetes-drugs-though-exact-damages-are-unclear/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-20-2021-1634716803.pdf
https://endpts.com/eli-lillys-recently-recalled-glucagon-kits-were-produced-at-troubled-indianapolis-site-report/
https://www.biospace.com/article/eli-lilly-voluntarily-recalls-entire-lot-of-glucagon-emergency-kits-in-the-us-canada/?s=71
https://www.pharmacompass.com/pdf/news/eli-lilly-co-issues-voluntary-nationwide-recall-of-glucagon-emergency-kit-1632722363.pdf
https://www.businesswire.com/news/home/20210212005054/en/Xeris-Pharmaceuticals-Receives-European-Commission-Approval-of-Ogluo%E2%84%A2-glucagon-Injection-for-the-Treatment-of-Severe-Hypoglycaemia-in-Adults-Adolescents-and-Children-Aged-2-Years-and-Over-With-Diabetes-Mellitus
https://www.prnewswire.com/news-releases/us-fda-grants-orphan-drug-designation-to-amidebios-glucagon-analog-for-the-treatment-of-congenital-hyperinsulinism-301045900.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212097
https://in.reuters.com/article/us-lilly-fda/eli-lillys-hypoglycemia-treatment-wins-fda-approval-idINKCN1UJ344
https://www.biospace.com/article/startup-neuraly-launches-with-36-million-targets-neurodegenerative-diseases/
https://www.businesswire.com/news/home/20180718005208/en/Startup-Neuraly-Raises-36M-Bring-Potential-Disease-Modifying
http://www.pharmatimes.com/news/eu_green_light_for_cimzia_to_treat_psoriasis_1243024
https://endpts.com/xeris-hauls-55m-in-new-funding-to-bring-glucagon-pen-to-market/
http://www.biospace.com/News/xeris-pharmaceuticals-scores-41-million-series-c/404775/source=TopBreaking
Market Place
Share 
